Search or
𝛼SK
𝛼SKbearish
Kaken Pharmaceutical (4521 JP): Johnson Deal Is Good For Future, But For Now Bleak H2 Ahead
626 Views06 Jan 2025 18:18
SUMMARY
- Kaken Pharmaceutical (4521 JP) enters into a license agreement with J&J for the global development, manufacturing, and commercialization of a STAT6 program, which is being developed by Kaken.
- Kaken will advance KP-723 to the completion of Phase I clinical trials, after which J&J will take over. Kaken will receive an upfront payment of $30M from J&J.
- The deal is a boost for future revenue flow but offers no near-term respite for revenue loss from NHI drug price revision and generic competition for top selling products.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Kaken Pharma (4521 JP): Bleaker FY26 Ahead, Growth Pangs to Continue for Now19 Nov 2025
- Kaken Pharma (4521 JP): FY26 Starts on a Bleak Note as Expected, Growth Pangs to Stay for Now13 Sep 2025
- Kaken Pharmaceutical (4521 JP): Bleak FY26 Ahead, No Immediate Respite In Sight20 May 2025
- Kaken Pharmaceutical (4521 JP): One-Off Payment Boosts H1FY25 Revenue; Headed for Another Bleak H226 Nov 2024
- Kaken Pharmaceutical (4521 JP): Key Operating Parameters Weakened in H1; H2 Not Seem to Be Better28 Nov 2023
- Kaken Pharmaceutical (4521 JP): Q1 Revenue Is Flat; Profit Falls; Bleak Outlook for FY2415 Aug 2023
x